Sector News

Fujifilm makes yet another deal to jack up cell and gene therapy capacity

March 27, 2022
Life sciences

In 2018, Japanese multinational conglomerate Fujifilm up and decided it wanted to become a major player in supplying cell and gene therapy manufacturing, so it purchased two key companies—one in the U.S. and in the other in Japan—to jump-start its goal.

Four years later, the spending spree continues: Fujifilm has gobbled up Shenandoah Biotechnology for an undisclosed sum, again to increase its cell and gene therapy capabilities.

The Warminster, Pennsylvania-based Shenandoah boosts Fujifilm’s ability to produce recombinant proteins—especially growth factors and cytokines—used in manufacturing cell and gene therapies.

Shenandoah also comes with an upgraded cGMP facility with bio-command software, a new Tuttnauer autoclave sterilizer, a 16×16 ColdBox, and new air handling and RODI water systems, according to its website.

“Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs,” Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific, said in a release.

Fujifilm said it welcomed “all members” of the Shenandoah team. The privately held company was established in 2006.

In 2018, Fujifilm dove headfirst into the cell and gene therapy supply business with its simultaneous acquisition of Irvine Scientific Sales of California and IS Japan for $800 million.

Then, in September of last year, Fujifilm completed construction of a 250,000-square-foot facility in Tilburg, Netherlands. The site produces dry powder media and liquid media along with other raw materials used in producing cell and gene therapies. It also gave Fujifilm Irvine Scientific a hub from which to serve its customers in Europe.

By Kevin Dunleavy

Source: fiercepharma.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach